To include your compound in the COVID-19 Resource Center, submit it here.

Alzumab's (re)mission statement

How Biocon aims to take on anti-TNF-alpha mAbs by targeting CD6

Biocon Ltd. is betting the long remission time and reduced opportunistic infections associated with its Alzumab itolizumab will pull doctors away from biologics with better efficacy in psoriasis.

The company has long maintained that the first-in-class biologic has a safety advantage over competing psoriasis biologics. Now the long-term data it is collecting from its psoriasis trials are providing a new selling point for the drug - duration of remission.

It's still unclear whether those benefits will be enough to pull

Read the full 783 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers